Clinical outcomes of modified partial cystectomy in muscle-invasive bladder cancer: balancing tumor control and quality of life

改良部分膀胱切除术治疗肌层浸润性膀胱癌的临床结果:平衡肿瘤控制与生活质量

阅读:1

Abstract

BACKGROUND: Muscle-invasive bladder cancer (MIBC) is highly aggressive with poor prognosis. Radical cystectomy (RC) with urinary diversion, the standard treatment, impairs patients' quality of life. This study explored modified partial cystectomy (MPC) as a bladder-preserving option, assessing oncological control, perioperative outcomes, and quality of life. METHODS: Patients who underwent partial cystectomy for urothelial carcinoma at the Affiliated Cancer Hospital of Guangzhou Medical University between January 2020 and January 2022 were included. Some received standard laparoscopic partial cystectomy (LPC), while others received MPC with laparoscopic pelvic lymph node dissection and open tumor resection. These were compared with a gold standard group undergoing RC and lymph node dissection, evaluating perioperative, functional, and oncological outcomes. RESULTS: Among the 57 patients (16 MPC, 18 LPC, 23 RC), LPC patients were older, RC tumors were more commonly located on the trigone, and tumors in the RC group were larger. Major complications were 21.7% in RC, vs. 5.5% in LPC and 6.2% in MPC (P<0.001). Positive margins occurred in 16.67% of LPC patients, and none occurred in MPC or RC (P=0.03). MPC and LPC had similar quality-of-life scores. After 36 months of follow-up, relapse rates were 34.7% in RC, 33.3% in LPC, and 6.2% in MPC (P=0.19). MPC had significantly longer 3-year recurrence-free survival than LPC (P=0.048) and RC (P=0.034), with comparable overall survival across groups. CONCLUSIONS: MPC surpasses LPC in tumor resection, reducing recurrence and enhancing survival. MPC also achieves similar oncological results to RC, making it a promising bladder-preserving alternative for MIBC patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。